Peptide Therapeutics Market Research, 2031
The global peptide therapeutics market was valued at $33.3 billion in 2021, and is projected to reach $64.3 billion by 2031, growing at a CAGR of 6.8% from 2022 to 2031. Peptide treatments refer to the use of peptides or polypeptides in the treatment of diseases. The functions that naturally occurring peptides can carry out as hormones, growth factors, ion channel ligands, and anti-effectiveness are replicated in peptide therapeutics. A wide range of therapeutic indications, including diabetes, gastrointestinal and metabolic problems, and hormonal disorders, are indicated for the treatment using approved peptides.
The market for peptide therapeutics is expected to grow as a result of a number of factors, including an increase in number of elderly people, an increase in prevalence of chronic diseases, and a rise in patient awareness about peptide therapeutics advancements. In addition, a prominent market trend that is anticipated to boost growth in the upcoming years is the rise in product development and technical improvements.
Due to enhanced manufacturing, modification, and analysis technology in recent years, peptide medicine research has made considerable developments. The fundamental constraints of peptides have been overcome, allowing for the market growth. There is a definite upward trend in metabolic disorders such as diabetes, obesity along with rise in cardiovascular diseases and cancer due to adaption of modern and unhealthy lifestyle. Thus, aforementioned factors drive the peptide therapeutics market opportunity.
However, low bioavailability of peptides along with high cost associated with the drug development are expected to hinder the market growth. Conversely, high growth potential for oral peptide therapeutics market, owing to rise in purchasing power in emerging economies is a lucrative opportunity for the peptide therapeutics market growth.
Impact of COVID-19
The COVID-19 epidemic is predicted to have a moderately positive impact on the growth of the global peptide therapeutics industry. Many peptide drugs were under clinical trials for the COVID_19 treatment. Furthermore, it is anticipated that the strong government support for the use of peptides in the creation of the COVID-19 vaccine would create a variety of chances for peptide adoption, ultimately accelerating the expansion of the market for peptide treatments. As of May 2020, 15 synthetic peptides were being used to treat ARDS and other respiratory conditions brought on by the SARS-Cov-2 virus, bringing the total number of peptide drugs available for the treatment of COVID-19 to 21.
Peptide Therapeutics Market Segmentation
The global peptide therapeutics market is segmented on the basis of application, route of administration, distribution channel, and region. On the basis of application, the market is categorized into metabolic, oncology, gastrointestinal, neurological, cardiovascular and others. By route of administration, it is divided into oral and parenteral. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online pharmacies. Hospital pharmacies is further bifurcated as private and public. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
Segment Review
By application, the market is segmented into metabolic, oncology, gastrointestinal, neurological, cardiovascular and others. The metabolic segment dominated the peptide therapeutics market size in 2021, owing to high prevalence of metabolic disorders and growing geriatric population susceptible to metabolic disorder. The oncology segment is expected to witness highest CAGR during the forecast period, owing to rise in cases of cancer globally and the presence of a strong product pipeline.
Depending on route of administration, the market is divided into oral and parenteral. The parenteral segment dominated the peptide therapeutics market size in 2021, owing to high rate of acceptance, quick drug delivery, and simple application. The oral segment is expected to witness highest CAGR during the forecast period owing to compliance with oral route and acceptance by patients.
Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the peptide therapeutics market share in 2021, owing to primarily responsible for monitoring the availability of all medications used in hospitals. The drug store & retail pharmacies segment is expected to witness highest CAGR during the forecast period owing to maintenance of treatment for long time and easy availability of drugs.
North America accounted for a majority of the global peptide therapeutics market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in peptide therapeutics techniques, integration of advanced devices and software processes in peptide therapeutics devices, presence of key market players and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing rise in geriatric population, development of healthcare infrastructure and increase in investment projects in the region.
The major players profiled in the peptide therapeutics industryreport are AbbVie Inc, Amgen Inc., Bausch Health Companies Inc, Eli Lilly and company, Ever Neuro Pharma Gmbh, GalaxoSmithKline plc, Novo Nordisk, Pfizer Inc, Sanofi-GSK and Takeda Pharmaceutical Company Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peptide therapeutics market analysis from 2021 to 2031 to identify the prevailing peptide therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the peptide therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global peptide therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Peptide Therapeutics Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 64.3 billion |
 Growth Rate | CAGR of 6.8% |
 Forecast period | 2021 - 2031 |
 Report Pages | 309 |
 By Application |
|
 By Route of administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Novo Nordisk A/S, Pfizer Inc., Baush Health, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Abbvie ( Allergan), Ever Neuro Pharma GmbH, Sanofi SA, Amgen Inc., GlaxoSmithKline plc |
Analyst Review
This section provides opinions of top level CXOs in the global peptide therapeutics market. According to the insights of CXOs, leading companies in the market, development of advanced and reliable peptide therapeutics has led to extensive number of applications of this drug. Increase in prevalence of chronic diseases and better healthcare services is also expected to propel the peptide therapeutics market.
Market growing at a steady rate in developed nations, Asia-Pacific and LAMEA are expected to offer high growth opportunities to key players in this market. According to the perspectives of CXOs of leading companies in the market, significant advancements in the peptide therapeutics with increase in clinically backed research, growing investments, funds, and grants, increasing incidence of chronic diseases, entry of new players, and growth in the geriatric population is projected to increase the sale of peptide therapeutics globally
Increase in number of elderly people, an increase in prevalence of chronic diseases, and peptide therapeutics advancements are the upcoming trends of peptide therapeutics market.
Metabolic is the leading application of peptide therapeutics market.
The global peptide therapeutics market was valued at $33,257.72 million in 2021, and is estimated to reach $64,336.12 million by 2031, growing at a CAGR of 6.8% from 2022 to 2031.
North America is the largest regional market for peptide therapeutics market.
AbbVie Inc, Amgen Inc., Bausch Health Companies Inc, Eli Lilly and company, Ever Neuro Pharma Gmbh, GalaxoSmithKline plc, Novo Nordisk, Pfizer Inc, Sanofi-GSK and Takeda Pharmaceutical Company Limited are the top companies to hold the market share in peptide therapeutics market.
2021 is the base year of peptide therapeutics market.
2022 to 2031 is the forecast period for peptide therapeutics market.
Loading Table Of Content...
